Considerations for Treating Pulmonary RRP
We are not “advocating” for any specific treatment modality. Any characterization to that effect is seriously off-base.
What we are advocating for is for the usage of modalities known to be more effective rather than less effective.
Patient may be on a ventilator, for example, but that does not suggest that methods should be used known to NOT work on pulmonary RRP. Systemic cidofovir is one of those methods. It often works interlesionally, yes, but we know of no reports whatsoever suggesting it does anything for pulmonary RRP when given systemically. On the contrary, all the “RRP experts” (physicians) whom we have heard from say that it does not work.
Based on several patient reports, interferon may be helpful in stabilizing pulmonary disease. Roferon, however, is known to have been implicated in a huge spike of neutralizing antibodies. This can actually be deleterious, causing a sudden rebound phenomena. Intron A has been measurably less implicated in the generation of these antibodies. We are also not a big fan of the arbitrary and very high dosing levels used by Healey and Kashima in their studies. More on all this at http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/272/#6.
Alternatively, Tarceva may be interesting. More on that at http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/366 .
We believe that there is substantial evidence to support a claim that artemisinin is at least as interesting as any of the previous adjuncts, however. For that, we would direct you to rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/273 and pages listed under that.
You may also wish to see http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/386 for material on this so-called "Task Force." Note too that the bibliographies are in the first link, esp. http://depts.washington.edu/bioe/about/news/artemisinin/artemisinin.html.
We would be most willing to discuss any or all of these approaches with you or your physician.
Also, we'd be happy to discuss an alternative method of treatment by artemisinin and its analogues that we believe is more potent, but that doesn’t appear on our website.
What we are advocating for is for the usage of modalities known to be more effective rather than less effective.
Patient may be on a ventilator, for example, but that does not suggest that methods should be used known to NOT work on pulmonary RRP. Systemic cidofovir is one of those methods. It often works interlesionally, yes, but we know of no reports whatsoever suggesting it does anything for pulmonary RRP when given systemically. On the contrary, all the “RRP experts” (physicians) whom we have heard from say that it does not work.
Based on several patient reports, interferon may be helpful in stabilizing pulmonary disease. Roferon, however, is known to have been implicated in a huge spike of neutralizing antibodies. This can actually be deleterious, causing a sudden rebound phenomena. Intron A has been measurably less implicated in the generation of these antibodies. We are also not a big fan of the arbitrary and very high dosing levels used by Healey and Kashima in their studies. More on all this at http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/272/#6.
Alternatively, Tarceva may be interesting. More on that at http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/366 .
We believe that there is substantial evidence to support a claim that artemisinin is at least as interesting as any of the previous adjuncts, however. For that, we would direct you to rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/273 and pages listed under that.
You may also wish to see http://www.rrpwebsite.org/index.cfm/fuseaction/category.display/category_ID/386 for material on this so-called "Task Force." Note too that the bibliographies are in the first link, esp. http://depts.washington.edu/bioe/about/news/artemisinin/artemisinin.html.
We would be most willing to discuss any or all of these approaches with you or your physician.
Also, we'd be happy to discuss an alternative method of treatment by artemisinin and its analogues that we believe is more potent, but that doesn’t appear on our website.